Clinical TrialJun 2, 2026, 04:07 PM
Vaxcyte Doses First Participant in Phase 1 VAX-A1 Strep A Vaccine Study
AI Summary
Vaxcyte announced the dosing of the first participant in its Phase 1, first-in-human study for VAX-A1, an investigational vaccine candidate for Group A Streptococcus (Group A Strep). The randomized, double-blind, placebo-controlled study in healthy adults aged 18-40 aims to evaluate safety, tolerability, and initial immunogenicity. Topline data from the study is anticipated in the second half of 2027. Group A Strep is a significant global public health challenge with no approved vaccine, causing approximately 800 million new cases and over 600,000 deaths annually.
Key Highlights
- Vaxcyte dosed the first participant in its Phase 1, first-in-human study for VAX-A1, a vaccine candidate for Group A Streptococcus.
- The randomized, double-blind, placebo-controlled, dose-escalation study will evaluate VAX-A1 in healthy adults aged 18 to 40 years.
- The primary objective is to assess safety and tolerability, with a secondary objective to evaluate initial immunogenicity data.
- The study is designed in two stages, enrolling approximately 80 healthy adults in total.
- Topline data from the Phase 1 study is anticipated in the second half of 2027.
- Group A Strep is responsible for an estimated 800 million new cases of illness and over 600,000 deaths annually worldwide.
- VAX-A1 is designed to provide broad protection against Group A Strep, a disease with no approved vaccine.
Price Impact
More from PCVX